Showing results (101-110 of 216) with videos related to

Sort By:
Pageof 22
Scientific Reports|January 24, 2020
Nearest Neighbour Propensity Score Matching and Bootstrapping for Estimating Binary Patient Response in Oncology: A Monte Carlo SimulationTine Geldof, Dusan Popovic, Nancy Van Damme, et al.
Frontiers in Pharmacology|June 17, 2017
Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi PanelTim A Kanters, Jelena Stevanovic, Isabelle Huys, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 26, 2024
Can Endangered Biosimilar Markets be Rescued? The Need to Bridge Competing Interests for Long-Term GainTeresa Barcina Lacosta, Arnold G Vulto, Florian Turk, et al.
Pharmaceuticals (Basel, Switzerland)|February 9, 2021
Informing Patients about Biosimilar Medicines: The Role of European Patient AssociationsYannick Vandenplas, Steven Simoens, Philippe Van Wilder, et al.
Pharmaceuticals (Basel, Switzerland)|June 2, 2021
Off-Patent Biologicals and Biosimilars Tendering in Europe-A Proposal towards More Sustainable PracticesLiese Barbier, Steven Simoens, Caroline Soontjens, et al.
Diabetes, Obesity & Metabolism|September 1, 2025
Barriers to adoption of biosimilar insulins in Europe: A mixed-methods studyElif Car, Garm Habets, Arnold G Vulto, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|August 24, 2022
How to select a best-value biological medicine? A practical model to support hospital pharmacistsLiese Barbier, Yannick Vandenplas, Niels Boone, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|April 5, 2019
Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2-Biosimilar and Originator Etanercept in the Outpatient SettingEvelien Moorkens, Steven Simoens, Per Troein, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|April 5, 2019
Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1-Biosimilar and Originator Infliximab in the Hospital SettingEvelien Moorkens, Steven Simoens, Per Troein, et al.
Frontiers in Medicine|March 26, 2021
Patient Preferences to Assess Value IN Gene Therapies: Protocol Development for the PAVING Study in HemophiliaEline van Overbeeke, Brett Hauber, Sissel Michelsen, et al.
Pageof 22